| Company Name: | Sangamo BioSciences, Inc. | | Ticker Symbol: | SGMO | | | WWW Address: | www.sangamo.com | | CEO: | Edward O. Lanphier, II | | No. of Employees: | 77 | | Common Issue Type: | CS | | Business Description: | The company is engaged in the research, development and commercialization of novel transcription factors for gene regulation and gene modification.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 5.33 |  -0.03 | 5.2 | 5.47 | 5.42 | 5.41 | 5.20 | 149033 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 240.7 | 44.9 | 1.61 | -0.60 | 0.00 | 0.0 | 0.0 | 9.39 - 2.00 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 5.36 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 240.7 | mil |
| Latest Shares Outstanding | 44.9 | mil |
| Earnings pS (EPS) | -0.60 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 210,208 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 37.2 | mil |
| Float as % of Shares Outstanding | 90.5 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 58.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 154.00 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.3 | % |
| Return on Assets (ROA) | -36.9 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -42.9 | % |
| Current Ratio | 6.9 | |
| Leverage Ratio (Assets/Equity) | 1.2 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 1.01 | $ |
| Cash pS | 0.33 | $ |
| Book-Value pS | 1.05 | $ |
| Tangible Book-Value pS | 1.05 | $ |
| Cash Flow pS | -0.42 | $ |
| Free Cash Flow pS | -0.28 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 5.10 | |
| Price/Tangible Book Ratio | 5.10 | |
| Price/Cash Flow | -12.7 | |
| Price/Free Cash Flow | -19.1 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -2.7 | 96 | 1,867 | 3,189 |
| 4 Weeks | 6.50 | 5.20 | 5.32 | 0.8 | 94 | 2,460 | 41,815 |
| 13 Weeks | 9.39 | 5.20 | 7.08 | -24.3 | 70 | 3,705 | 226,014 |
| 26 Weeks | 9.39 | 3.68 | 3.97 | 35.0 | 112 | 2,996 | 374,449 |
| 52 Weeks | 9.39 | 2.00 | 2.46 | 117.9 | 177 | 2,513 | 625,679 |
| YTD | 9.39 | 2.68 | - | 54.0 | 126 | 2,531 | 574,587 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 5.53 | 5.77 | 6.77 | 5.73 | 5.31 | 1.61 | 1.64 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 68.32 | 90.8 | 34.46 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 99.82 | NA | 34.13 |
| R&D | 26.22 | NA | 23.87 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 27.7 | 8.5 | 77.9 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.14 | 0.03 | -0.02 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 79.91 |
| Current Ratio | 5.7 |
| Quick Ratio (Acid Test) | 5.6 |
| Liquidity Ratio (Cash) | 5.57 |
| Receivables Turnover | 26.4 |
| Average Collection Period | 14 |
| Working Capital/Equity | 97.9 |
| Working Capital pS | 1.32 |
| Cash-Flow pS | -0.58 |
| Free Cash-Flow pS | -0.44 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 11.07 |
| Financial Leverage Ratio (Assets/Equity) | 1.2 |
| Debt Ratio | 18.4 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 1.5 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 2.98 |
| Tobin's Q Ratio | 3.55 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -7.58 |
| Enterprise Value (EV)/Free Cash Flow | -10.62 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 5.10 |
| Price/Book Ratio - LTM | 5.10 |
| Price/Cash Flow Ratio | -12.7 |
| Price/Free Cash Flow Ratio - LTM | -19.1 |
| Price/Sales Ratio | 12.82 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.28 |
| Tangible Book Value pS - LTM | 1.05 |
| Book Value pS - LTM | 1.05 |
| Capital Invested pS | 1.23 |
| Cash pS - LTM | 0.33 |
| Cash Flow pS - LTM | -0.42 |
| Free Cash Flow pS - LTM | -0.28 |
| Earnings pS (EPS) | -0.60 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -111.73 |
| Free Cash Flow Margin 5YEAR AVG | -289.51 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.29 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.29 |
| Return on Capital Invested (ROCI) | -43.9 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -36.8 |
| Assets Productivity | 0.20 |
| Return on Assets (ROA) | -35.8 |
| Return on Assets (ROA) - 5YEAR AVRG. | -31.2 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 99.8 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 15 |
| Revenue per Employee | 210,208 |
| Net Income per Employee | -315,610 |
| Average Collection Period | 15 |
| Receivables Turnover | 26.4 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 10.45 |
| Assets/Revenue | 5.00 |
| Net Working Capital Turnover | 0.30 |
| Fixed Assets Turnover | 8.10 |
| Total Assets Turnover | 0.2 |
| Revenue per $ Cash | 0.83 |
| Revenue per $ Plant | 8.15 |
| Revenue per $ Common Equity | 0.29 |
| Revenue per $ Capital Invested | 0.29 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 63.8 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 95.1 |
| Research & Devlopment (R&D) as % of Revenue | 192.9 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 192.9 |
|
|  
|
| |
 |  |